Activator protein-1 activity regulates epithelial tumor cell identity

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7578-7588

  Gerdes, Michael J ^a   Myakishev, Maxim ^a   Frost, Nicholas A ^a   Rishi, Vikas ^a   Moitra, Jaideep ^a   Acharya, Asha ^a   Levy, Michelle R ^a   Park, Sang Won ^a   Glick, Adam ^a   Yuspa, Stuart H ^a   Vinson, Charles ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MOLECULAR MARKER; NUCLEIC ACID BINDING PROTEIN; PROTEIN C JUN; SONIC HEDGEHOG PROTEIN; TETRACYCLINE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSA; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG; WNT PROTEIN;

ALOPECIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BENIGN SKIN TUMOR; CARCINOGENESIS; CELL LINEAGE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPITHELIUM CELL; HYPERPLASIA; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SEBACEOUS GLAND DISEASE; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR CELL;

ADENOCARCINOMA, SEBACEOUS; ANIMALS; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; HYPERPLASIA; KERATINOCYTES; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; SEBACEOUS GLANDS; SKIN NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; WNT PROTEINS;

EID: 33747875862     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1247     Document Type: Article

References (54)

1. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
2. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
3. Zenz R, Scheuch H, Martin P, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-89.
4. Li G, Gustafson-Brown C, Hanks SK, et al. c-Jun is essential for organization of the epidermal leading edge. Dev Cell 2003;4:865-77.
5. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 1999;96:9827-32.
6. Dlugosz A, Merlino G, Yuspa SH. Progress in cutaneous cancer research. J Investig Dermatol Symp Proc 2002;7:17-26.
7. Saez E, Rutberg SE, Mueller E, et al. c-fos is required for malignant progression of skin tumors. Cell 1995;82:721-32.
8. Thompson EJ, Gupta A, Stratton MS, Bowden GT. Mechanism of action of a dominant negative c-jun mutant in inhibiting activator protein-1 activation. Mol Carcinog 2002;35:157-62.
9. Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res 2003;1:848-54.
10. Bachelor MA, Cooper SJ, Sikorski ET, Bowden GT. Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model. Mol Cancer Res 2005;3:90-9.
11. Eckert RL, Efimova T, Balasubramanian S, Crish JF, Bone F, Dashti S. p38 Mitogen-activated protein kinases on the body surface: a function for p38delta. J Invest Dermatol 2003;120:823-8.
12. Chen N, Nomura M, She QB, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001;61:3908-12.
13. Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK. Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res 2001;61:808-12.
14. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by α-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Cancer Res 2003;63:3037-42.
15. Arnott CH, Scott KA, Moore RJ, et al. Tumour necrosis factor-α mediates tumour promotion via a PKC α- and AP-1-dependent pathway. Oncogene 2002;21:4728-38.
16. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 2000;1:181-8.
17. Rutberg SE, Adams TL, Glick A, Bonovich MT, Vinson C, Yuspa SH. Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes. Cancer Res 2000;60:6332-8.
18. Casanova ML, Larcher F, Casanova B, et al. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002;62:3402-7.
19. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
20. Newman JR, Keating AE. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science 2003;300:2097-101.
21. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 2002;22:6321-35.
22. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997;272:18586-94.
23. Diamond I, Owolabi T, Marco M, Lam C, Glick A. Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter. J Invest Dermatol 2000;115:788-94.
24. Rincon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J 1994;13:4370-81.
25. Moll JR, Acharya A, Gal J, Mir AA, Vinson C. Magnesium is required for specific DNA binding of the CREB B-ZIP domain. Nucleic Acids Res 2002;30:1240-6.
26. Rutberg SE, Saez E, Glick A, Dlugosz AA, Spiegelman BM, Yuspa SH. Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins. Oncogene 1996;13:167-76.
27. Rehman I, Lowry DT, Adams C, et al. Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N′-nitro-N-nitrosoguanidine and promoted by mezerein. Mol Carcinog 2000;27:298-307.
28. Bohlander SK, Espinosa R III, Le Beau MM, Rowley JD, Diaz MO. A method for the rapid sequence-independent amplification of microdissected chromosomal material. Genomics 1992;13:1322-4.
29. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 1997;38:2249-63.
30. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
31. Niemann C, Unden AB, Lyle S, Zouboulis Ch C, Toftgard R, Watt FM. Indian hedgehog and β-catenin signaling: role in the sebaceous lineage of normal and neoplastic mammalian epidermis. Proc Natl Acad Sci U S A 2003;100 Suppl 1:11873-80.
32. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61:1315-27.
33. Niemann C, Owens DM, Hulsken J, Birchmeier W, Watt FM. Expression of DeltaNLef1 in mouse epidermis results in differentiation of hair follicles into squamous epidermal cysts and formation of skin tumours. Development 2002;129:95-109.
34. Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002;24:811-20.
35. Alonso L, Fuchs E. Stem cells in the skin: waste not, Wnt not Genes Dev 2003;17:1189-200.
36. Weidinger G, Moon RT. When Wnts antagonize Wnts. J Cell Biol 2003;162:753-5.
37. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
38. Rivat C, Le Floch N, Sabbah M, et al. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003;17:1721-3.
39. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005;437:281-5.
40. Hwang SG, Yu SS, Lee SW, Chun JS. Wnt-3a regulates chondrocyte differentiation via c-Jun/AP-1 pathway. FEBS Lett 2005;579:4837-42.
41. Le Floch N, Rivat C, De Wever O, et al. The proinvasive activity of Wnt-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3β and c-Jun/AP-1 signaling. FASEB J 2005;19:144-6.
42. Hayakawa J, Mittal S, Wang Y, et al. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 2004;16:521-35.
43. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 2002;30:158-66.
44. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
45. Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res 2002;62:3044-7.
46. Sundberg JP, Erickson AA, Roop DR, Binder RL. Ornithine decarboxylase expression in cutaneous papillomas in SENCAR mice is associated with altered expression of keratins 1 and 10. Cancer Res 1994;54:1344-51.
47. Mann B, Gelos M, Siedow A, et al. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8.
48. van den Brink GR, Bleuming SA, Hardwick JC, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 2004;36:277-82.
49. Li W, Qiao W, Chen L, et al. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development 2003;130:6143-53.
50. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-43.
51. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-7.
52. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36 Suppl 1:59-72.
53. Gerdes M, Yuspa S. The contribution of epidermal stem cells to skin cancer. Stem Cell Reviews 2005;1:225-32.
54. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004;429:41-6.